D Pharm (Israel) Financial Diagnostics

DPRM -- Israel Stock  

ILS 430.00  0.60  0.14%

D Pharm LTD diagnostics interface makes it easy to digest most current publicly released information about D Pharm as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis D Pharm price relationship with some important fundamental indicators such as market cap and management efficiency.

D Pharm Note

The company recorded loss per share of 0.14. D Pharm LTD had not issued any dividends in recent years. This company had 1:50 split on 2016-02-21. D-Pharm LTD., a drug-development company, focuses on the development of drugs for the treatment of central nervous system conditions. D-Pharm LTD. was founded in 1993 and is based in Rehovot, Israel. D Pharm operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. To learn more about D-PHARM call Golan Bitton at 972 8 938 5100 or check out http://www.dpharm.com.

D Pharm LTD Alerts

D Pharm LTD is not yet fully synchronised with the market data
The company reported revenue of 723 K. Net Loss for the year was (814 K) with profit before overhead, payroll, taxes, and interest of 723 K.
D-PHARM has accumulated about 314 K in cash with (313 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05.

Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 26.75 M.

Profitablity

The company has Profit Margin (PM) of (112.59) % which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (100.69) % which suggests for every $100 dollars of sales it generated a net operating loss of -1.01.

Management Efficiency

D Pharm LTD has return on total asset (ROA) of (42.09) % which means that it has lost $42.09 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (400.0) % meaning that it generated substantial loss on money invested by shareholders.

D Pharm Technical and Predictive Indicators

Did you try this?

Run Companies Directory Now

   

Companies Directory

Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
All  Next Launch Companies Directory

Also Currentnly Active

Purchased over 200 shares of
few hours ago
Traded for 6.68
Purchased over 100 shares of
few hours ago
Traded for 11.39
Purchased over 200 shares of
few hours ago
Traded for 9.0
Additionally see Investing Opportunities. Please also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Search macroaxis.com